I-Mab obtains license for research new drug from China's State Drug Administration
-
Last Update: 2020-06-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, I-Mab Biopharma Bio
Pharmaceutical(http://company(http://and MorphoSys AG, a German biopharmaceutical company, announced that I-Mab had been licensed by the China NationalMedicines(http://Regulatory Authority (NMPA) for the
researchhttp://(IND)
I-Mab is currently conducting two clinicaltrial strial strial spree (http://trials in Taiwanhttp://The Second Study was launched in March 2019 to assess the efficacy and safety of TJ202/MOR202 as a third-line treatment for patients with recurrent or refractory MM The third phase of the study, launched in April 2019, assessed the effectiveness and safety of the combination of TJ202 /MOR202 Calais amine (LEN) and dexamethasone (DEX) with a combination of LEN and DEX in patients with recurrent or refractory MM I-Mab will now extend these tests to Chinese mainland, based on a rapid lying development strategy About TJ202 / MOR202
TJ202 / MOR202 is a research human monoclonal antibody developed and produced using MorphoSys HuCAL antibody technology The antibody targets CD38 on the surface of multiple myeloma cells, which has been characterized as one of the strongest and most uniformly expressed antigens on the surface of malignant plasma cells
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
